AFM13 Plus AB-101 to Be Tested in Phase 2 Study
The ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.
MammaPrint May Predict Neoadjuvant Chemo Response in HR+, HER2- Early Breast Cancer
The MammaPrint and BluePrint tests may be able to predict which patients with HR-positive, HER2-negative breast cancer are most likely to respond to neoadjuvant chemotherapy.